"Tuberculosis, Pulmonary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
MYCOBACTERIUM infections of the lung.
| Descriptor ID |
D014397
|
| MeSH Number(s) |
C01.252.410.040.552.846.899 C08.381.922 C08.730.939
|
| Concept/Terms |
Tuberculosis, Pulmonary- Tuberculosis, Pulmonary
- Tuberculoses, Pulmonary
- Pulmonary Tuberculoses
- Pulmonary Tuberculosis
- Pulmonary Consumption
- Consumption, Pulmonary
- Consumptions, Pulmonary
- Pulmonary Consumptions
- Pulmonary Phthisis
- Phthises, Pulmonary
- Phthisis, Pulmonary
- Pulmonary Phthises
|
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Pulmonary".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Pulmonary".
This graph shows the total number of publications written about "Tuberculosis, Pulmonary" by people in this website by year, and whether "Tuberculosis, Pulmonary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 4 | 0 | 4 |
| 2008 | 1 | 1 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 4 | 1 | 5 |
| 2013 | 3 | 0 | 3 |
| 2014 | 2 | 1 | 3 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tuberculosis, Pulmonary" by people in Profiles.
-
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.
-
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial. Am J Respir Crit Care Med. 2022 05 15; 205(10):1228-1235.
-
Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2021 09 17; 65(10):e0179420.
-
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718.
-
Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. J Antimicrob Chemother. 2021 02 11; 76(3):582-586.
-
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020 03; 90:105938.
-
Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. J Infect Dis. 2019 10 08; 220(220 Suppl 3):S99-S107.
-
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrob Agents Chemother. 2019 04; 63(4).
-
Transmission of Mycobacterium tuberculosis From Patients Who Are Nucleic Acid Amplification Test Negative. Clin Infect Dis. 2018 11 13; 67(11):1653-1659.
-
Serologic Responses in Childhood Pulmonary Tuberculosis. Pediatr Infect Dis J. 2018 Jan; 37(1):1-9.